Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Collegium Pharmaceutical, Inc. has good value characteristics. Collegium Pharmaceutical, Inc. is not very popular among insiders. Collegium Pharmaceutical, Inc. is a mediocre stock to choose.
Log in to see more information.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing...
COLL Fundamental Data by TradingView

News

Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why
Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why

Zacks Investment Research Collegium Pharmaceutical (COLL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings...\n more…

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Zacks Investment Research The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always...\n more…

The Analyst Landscape: 4 Takes On Collegium Pharmaceutical
The Analyst Landscape: 4 Takes On Collegium Pharmaceutical

Benzinga In the latest quarter, 4 analysts provided ratings for Collegium Pharmaceutical COLL, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.\n more…

Collegium Pharmaceutical price target raised by $3 at H.C. Wainwright, here's why
Collegium Pharmaceutical price target raised by $3 at H.C. Wainwright, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Collegium Pharmaceutical completes acquisition of Ironshore for $525M in cash
Collegium Pharmaceutical completes acquisition of Ironshore for $525M in cash

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Collegium Completes Acquisition of Ironshore Therapeutics
Collegium Completes Acquisition of Ironshore Therapeutics

Globe Newswire Adds Commercial Product Jornay PM , Establishing Collegium's Presence in Neurology (ADHD) Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore...\n more…